
-
Verrica Pharmaceuticals NASDAQ:VRCA Verrica is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. Verrica's late-stage product candidate, VP-102, is in development to treat molluscum contagiosum (molluscum), common warts and external genital warts, three of the largest unmet needs in medical dermatology. Verrica is also developing VP-103, its second cantharidin-based product candidate, for the treatment of plantar warts. The Company has also entered a worldwide license agreement with Lytix Biopharma AS to develop and commercialize LTX-315 for dermatologic oncology conditions.
Location: 10 N High St Ste 200, Pennsylvania, 19380-3014, US | Website: www.verrica.com | Industry: Medicinal and Botanical Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
44.5M
Cash
46.33M
Avg Qtr Burn
-15.23M
Short % of Float
15.81%
Insider Ownership
42.98%
Institutional Own.
32.13%
Qtr Updated
12/31/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
YCANTH (VP-102) Details Infectious disease, Molluscum contagiosum | Approved Quarterly sales | |
YCANTH (VP-102) Details Human papillomavirus, Genital Warts
| Phase 3 Initiation | |
VP-315 Details Basal cell carcinoma | Phase 2 Data readout |